FinancialContent is the trusted provider of stock market information to the media industry.
March 08, 2012 at 12:31 PM EST
Dendreon Drops On Johnson & Johnson's Upbeat Trial Results

Shares of Provenge maker Dendreon Corp. (Nasdaq: DNDN) tumbled 93 cents to $9.95 after Johnson & Johnson (NYSE: JNJ) reported positive results from a late stage clinical trial of its prostate cancer treatment Zytiga. Johnson & Johnson stock gained 66 cents to $64.96.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More